
NCPA Backs New Senate Bill to End Retroactive 'DIR Fees,' Improve Medicare Transparency
Four U.S. Senators today introduced bipartisan legislation to boost transparency in Medicare Part D drug spending and to prohibit retroactive "DIR fees" in response to concerns raised by National Community Pharmacists Association (NCPA) members and staff.
PRESS RELEASE ALEXANDRIA, Va. (Sept. 12, 2016) Four U.S. Senators today introduced bipartisan legislation to boost transparency in Medicare Part D drug spending and to prohibit retroactive "DIR fees" in response to concerns raised by National Community Pharmacists Association (NCPA) members and staff.
Senators Shelley Moore Capito (R-W.Va.), Jon Tester (D-Mont.), John Boozman (R-Ark.) and Tom Cotton (R-Ark.) have introduced the "Improving Transparency and Accuracy in Medicare Part D Spending Act," S. 3308. Companion legislation to
In response to the bill's introduction, NCPA CEO B. Douglas Hoey, RPh, MBA, issued the following statement:
"Since the inception of the Medicare Part D drug benefit, independent community pharmacists have tirelessly served seniors to help them get the most out of the program. Over the years Medicare officials and Congress have occasionally stepped in to make enhancements so Part D operates more smoothly. That action is certainly needed now to address out-of-control DIR fees.
"In banning retroactive DIR fees, S. 3308 / H.R. 5951 would improve transparency in Medicare Part D as
"NCPA congratulates Sens. Capito and Tester and their colleagues on introduction of this important legislation. It would go a long way to addressing the problems that NCPA has raised and educated Congress, Medicare and others about.
"I encourage NCPA members to take grassroots action
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.